HK StockDetailed Quotes

Provided by TTMF Limited

MABWELL-BUnlisted

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:- -

Open:- -

Low:- -

Close:- -

52wk High:- -

52wk Low:- -

Shares:400.00M

HK Float Shares:400.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

PS:- -

1

Offering

Apr 20

2

Closed

Apr 23 10:15

3

IPO Result

Apr 24

4

Grey Mkt.

Apr 27 16:15 - 18:30

5

Listing

Apr 28

Overview Company News Filings

Company Profile

Company Name:

MABWELL-B

Exchange:

SEHK

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

https://www.mabwell.com/

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

The company is an innovative biopharmaceutical enterprise with end-to-end, full-industry-chain integration. Adhering to the vision of "turning innovation from a dream into reality" and upholding the mission of "exploring life to benefit health," it leverages breakthrough, first-in-class innovation to deliver biologic innovators that offer superior efficacy and greater accessibility, thereby addressing unmet clinical needs worldwide. The company's core business encompasses the research and development, manufacturing, and commercialization of innovative medicines and biosimilars. Its principal product portfolio includes antibodies, antibody–drug conjugates, recombinant proteins, small-molecule chemical drugs, and other therapeutic agents. The company has been recognized with numerous awards, including the Shanghai Industrial Talent Development Initiative's "Outstanding Case Award," the Institute of Chartered Accountants in Australia's "Recognized Employer" designation, the Starlight List's "2021 China Biologics Innovation Drug Most Promising Growth Award," as well as top honors on the China Pharmaceutical Talent Brand Ranking and the Most Competitive Brand list.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02493/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02493","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"MABWELL-B","latestPrice":0,"timestamp":1776672000000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":400000000,"shares":400000000,"eps":0,"marketStatus":"To be listed","change":0,"latestTime":"04-20 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":8,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1776648600000,1776657600000],[1776661200000,1776672000000]],"volumeRatio":0,"ipoDetail":{"name":"迈威生物－Ｂ","exchange":"SEHK","listingDate":"2026-04-28","sharesOutstanding":446730200,"sharesFloat":446730200,"offerAmount":47130200,"priceRange":"27.640 - 30.710","market":"HK","openProspectusDate":"2026-04-20","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0420/2026042000012_c.pdf","purchaseBeginDate":"2026-04-20","purchaseEndDate":"2026-04-23","winningDate":"2026-04-27","currency":"HKD","minPurchaseQuantity":200,"peRate":-12.17,"use":"1、约56.8%，或713.0百万港元将用于核心产品9MW2821针对多种适用症不同阶段的临床开发试验；\n2、约17.7%，或222.3百万港元将用于针对具有大量临床需求的肿瘤和年龄相关疾病的其他管线产品的研发；\n3、约15.5%，或194.7百万港元将用于商业化目的；\n4、约10.0%，或125.6百万港元将用于营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司成立于2017年，是一家以药物研发方面的创新能力以及从药物发现至商业化销售的端到端能力而闻名的中国制药公司。公司主要专注于自主开发肿瘤、免疫、眼科、骨科等领域的药物。公司建立了管线产品组合，包括10个以上不同品种的药物资产，包括一款自研核心产品9MW2821（bulumtatug fuvedotin （「BFv」），靶向Nectin-4的ADC候选药物）。","subscribed":19.83,"marketCap":12348000000,"minimumCapital":6203.95,"overAllotment":false,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,2000000,2356600","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-04-27","greyDateTimestamp":1777219200000,"greyOpeningTime":1777277700000,"greyClosingTime":1777285800000,"showGreyQuote":false,"openProspectusDate":"2026-04-20","listingDate":"2026-04-28"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","floatShares":400000000,"roa":"--","roe":"--","lyrEps":0,"shares":400000000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02493\",,undefined,":{"id":9896,"type":"COMMON","ipoName":"02493-IPO","symbol":"02493","companyName":"MABWELL-B","market":"HK","currency":"HKD","status":"OPEN","underwriter":"中信证券(香港)有限公司","lotSize":200,"minQty":200,"expectedOfferingSize":47130200,"openingDate":1776648600000,"closingDate":1776910500000,"commonClosingDate":1776910500000,"allotmentDate":1776960000000,"listDate":1777305600000,"marginable":true,"marginRate":10,"latestPrice":30.71,"minPrice":27.64,"maxPrice":30.71,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0420/2026042000011.pdf","allowedQuantities":[200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,2000000,2356600],"interestRate":0,"recommend":false,"isHint":false,"interestStartDate":1776873600000,"interestEndDate":1776873600000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1777277700000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[{"ipoName":"02493-IPO","ipoId":9896,"financingId":59183,"type":1,"availableFundLimit":6203.94,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":62039.4,"maxSubscribeLimit":-1,"marginRate":10,"interestRate":0,"openTime":1776648600000,"closeTime":1776910500000,"isAtValidTime":true,"subscriptionMethod":"FINANCING","processFee":0,"supportPI":false,"applyFundLimit":6203.94,"threshold":50000000000,"isAvailable":false},{"ipoName":"02493-IPO","ipoId":9896,"financingId":59176,"type":4,"availableFundLimit":6203.94,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":0,"maxSubscribeLimit":-1,"marginRate":100,"interestRate":0,"openTime":1776648600000,"closeTime":1776910500000,"isAtValidTime":true,"subscriptionMethod":"CASH","processFee":0,"supportPI":false,"applyFundLimit":6203.94,"threshold":50000000000,"isAvailable":false}],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[{"method":"CASH","closeTime":1776910500000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":6203.94},{"method":"FINANCING","closeTime":1776910500000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":6203.94}],"latestClosingDate":1776910500000,"subscribedFinanceRatio":19.83,"subscribedRatio":19.83,"forecastRatio":28.75,"raiseMoney":144740000,"totalMargin":2870590000,"quoteInfoUpdatedAt":1776704935896,"forecastMarketValue":13033353585,"minForecastMarketValue":12347622728,"maxForecastMarketValue":13719084442,"sharesOutstanding":446730200,"business":"公司成立于2017年，是一家以药物研发方面的创新能力以及从药物发现至商业化销售的端到端能力而闻名的中国制药公司。公司主要专注于自主开发肿瘤、免疫、眼科、骨科等领域的药物。公司建立了管线产品组合，包括10个以上不同品种的药物资产，包括一款自研核心产品9MW2821（bulumtatug fuvedotin （「BFv」），靶向Nectin-4的ADC候选药物）。","greyOpeningTime":1777277700000,"greyClosingTime":1777285800000,"tradable":true,"showClawback":true,"clawbackType":"Mechanism B","clawbackRate":10},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"https://www.mabwell.com/","compareEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":0.0052},{"period":"3month","weight":-0.0255},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.2227},{"period":"ytd","weight":0.0207}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"The company is an innovative biopharmaceutical enterprise with end-to-end, full-industry-chain integration. Adhering to the vision of \"turning innovation from a dream into reality\" and upholding the mission of \"exploring life to benefit health,\" it leverages breakthrough, first-in-class innovation to deliver biologic innovators that offer superior efficacy and greater accessibility, thereby addressing unmet clinical needs worldwide. The company's core business encompasses the research and development, manufacturing, and commercialization of innovative medicines and biosimilars. Its principal product portfolio includes antibodies, antibody–drug conjugates, recombinant proteins, small-molecule chemical drugs, and other therapeutic agents. The company has been recognized with numerous awards, including the Shanghai Industrial Talent Development Initiative's \"Outstanding Case Award,\" the Institute of Chartered Accountants in Australia's \"Recognized Employer\" designation, the Starlight List's \"2021 China Biologics Innovation Drug Most Promising Growth Award,\" as well as top honors on the China Pharmaceutical Talent Brand Ranking and the Most Competitive Brand list.","exchange":"SEHK","name":"MABWELL-B","nameEN":"MABWELL-B"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"02493\",market:\"HK\",,,undefined,":null}}